# US 8,785,369 B2 · Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,369 B2
- Document ID: US8785369B2
- Status: Granted
- Kind: B2
- Application number: 12/359,773
- Filed: 2009-01-26
- Published: 2009-06-18
- Granted: 2014-07-22
- Earliest claimed: 2005-09-02
- Assignees: Morehouse School of Medicine
- Applicants: Byron D. Ford
- Inventors: Byron D. Ford
- Web page: https://patentgrep.com/patent/US8785369B2

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- Y10S 977/915: Therapeutic or pharmaceutical composition
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement of stem cell migration from the ventricle to the site of injury to the brain.

## Claims

### Claim 1

A method for ameliorating occlusive stroke damage in a patient by increasing migration of neural stem cells to damaged areas of the brain, comprising the step of:
administering an effective neural stem cell migration-inducing and inflammation inhibiting amount of neuregulin-1 to a patient who has suffered an occlusive stroke, wherein said neuregulin-1 is administered within about 13.5 to 72 hours after the onset of said occlusive stroke.

### Claim 2 (depends on 1)

The method of claim 1, wherein said neuregulin-1 is administered with a carrier, and wherein the carrier is serum albumin.

### Claim 3 (depends on 2)

The method of claim 2, wherein said serum albumin is human serum albumin.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dosage of neuregulin-1 administered is 0.05 to 100 ng/kg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dosage of neuregulin-1 administered is 0.05 to 5 ng/kg.

### Claim 6 (depends on 1)

The method of claim 1, wherein said patient is additionally administered with tissue plasminogen activator (t-PA).

### Claim 7 (depends on 1)

The method of claim 1, wherein said patient is additionally administered with a glutamate receptor inhibitor.

### Claim 8 (depends on 7)

The method of claim 7, wherein said glutamate receptor inhibitor is dizocilpin maleate.

### Claim 9 (depends on 1)

The method of claim 1, wherein said neuregulin-1 is administered into the cerebral spinal fluid of said patient by injection at the lumbar region.

### Claim 10 (depends on 1)

The method of claim 1, wherein said neuregulin-1 is administered via an intrathecal route.

### Claim 11 (depends on 1)

The method of claim 1, wherein said neuregulin is administered via a shunt into the ventricle or subventricular zone.

### Claim 12 (depends on 1)

The method of claim 1, wherein said neuregulin-1 is administered intravenously or intra-arterially.

### Claim 13 (depends on 1)

The method of claim 1, wherein said neuregulin-1 is administered into the carotid artery.

### Claim 14 (depends on 1)

The method of claim 1, wherein said neuregulin-1 is administered within about 13.5 to 24 hours after the onset of said occlusive stroke.

### Claim 15 (depends on 1)

The method of claim 1, wherein said neuregulin-1 is administered within 24-72 hours after the onset of said occlusive stroke.

### Claim 16

A method for ameliorating occlusive stroke damage in a patient, comprising:
administering an effective amount of neuregulin-1 to a patient who has suffered an occlusive stroke, wherein said neuregulin-1 is administered within about 13.5 to 72 hours after the onset of said occlusive stroke.

### Claim 17 (depends on 16)

The method of claim 16, wherein said patient is additionally administered with tissue plasminogen activator (t-PA).

### Claim 18 (depends on 16)

The method of claim 16, wherein said neuregulin-1 is administered intravenously, intraarterially or intrathecally.

### Claim 19 (depends on 16)

The method of claim 16, wherein said neuregulin-1 is administered within about 13.5 to 24 hours after the onset of said occlusive stroke.

### Claim 20 (depends on 16)

The method of claim 16, wherein said neuregulin-1 is administered within 24-72 hours after the onset of said occlusive stroke.